EAHP represents over 30,000 hospital pharmacists across 37 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professional
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic, Germany, Italy and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
The Early Career Network aims to empower early-career pharmacists by sharing opportunities, insights, and success stories from across 25 member countries.
Together, we’re building a stronger, more connected hospital pharmacy community: one story, one country, one pharmacist at a time.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Highlights from the EAHP Congress in pictures.
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
On 16 December 2025, the European Commission published its proposal for a Biotech Act I with a focus on health biotechnologies. EAHP acknowledges the proposal as a step forward to support innovative biotechnologies going from scientific discoveries to new products more swiftly in the healthcare sector. However, further efforts are needed to guarantee that the measures improve public health and patients access to these new technologies. The proposal should ensure the following:
The EAHP opinion on the Biotech Act I is available HERE.
As the EU co-legislators shape their respective positions on the European Biotech Act, EAHP alongside the other undersigned organisations advocating for improved access to medical tools and healthcare, urge members of the European Parliament and Representatives of the Council of the European Union to ensure that the legislation strengthens the Union’s biotechnology and biomanufacturing sectors while promoting innovation that is accessible and affordable in a timely manner, and responsive to public health needs.
The signatories call on the co-legislators to reject any extension of the Supplementary Protection Certificates (SPCs), which would prolong market monopolies and delay access to more affordable medicines and other medical products. The act should also ensure that publicly supported strategic projects, research and innovation include binding and enforceable access commitments so that technologies developed with EU support are available and affordable to all who need them.
Read the complete joint statement including the justifications for these proposals HERE.
Advanced therapy medicinal products (ATMPs) are innovative and complex medicines used to treat a variety of human health issues. Areas of application include, but are not limited to, cancers, neurodegenerative diseases, inherited diseases and autoimmune diseases. In particular, patients suffering from severe, rare or chronic diseases might benefit in the future from the growing use of ATMPs. Hospital pharmacists are responsible for ensuring the safe and effective use of medicines. This expertise of the pharmacy workforce should be a central component to adequate delivery of ATMPs within hospitals. Their participation is not only invaluable in clinical trials for ATMPs where they are responsible for the correct receipt, storage, distribution and control of the clinical trial drug, but also for routine clinical practice.
Since the use of ATMPs for the treatment of disease and injury is growing, EAHP adopted a position paper on this topic that outlines the roles and responsibilities of hospital pharmacists in the handling of ATMPs, addresses their education and training in relation to these products and provides insights on the assessment of ATMPs and pharmacoeconomics.
In its position paper, EAHP
EAHP’s Position Paper on Advanced Therapy Medicinal Products is available HERE
In July 2023, EAHP co-signed a joint statement on the ATMPs development within the Revision of the EU general pharmaceutical legislation with the European Alliance for Vision Research and Ophthalmology and the European Paediatric Translational Research Infrastructure.
The statement underlines that hospital pharmacists play a pivotal role as the handling of ATMPs as licensed medicines, falls under their responsibility and their knowledge of pharmacoeconomics and clinical evaluations are essential in assessing the added value of these products.
It is also highlighted that harmonised education and training of healthcare professionals are pivotal for coordinated practices of the hospital exemption including the development of European education and training materials with the integration of ATMP training in pharmacy and medicine schools. The collaboration of scientific societies involved across the entire ATMP spectrum is essential as well as of professional bodies offering continuing education programmes.
Have a look at the joint statement HERE
